New Serious Safety Warnings for Targeted Anticancer Agents After Their Initial FDA Approval

Area of Science:

• Pharmacovigilance
• Oncology
• Drug Safety

Background:

• Targeted anticancer agents (TAAs) are associated with emerging safety concerns post-approval.
• Understanding the long-term emergence of serious adverse drug reactions (ADRs) is crucial for patient safety.

Purpose of the Study:

• To investigate the continued emergence of serious and potentially fatal ADRs in updated TAA drug labels.
• To determine if the emergence of new ADRs can be predicted over time.

Main Methods:

• Analysis of updated U.S. FDA drug labels for TAAs approved before July 2013.
• Identification of serious and potentially fatal ADRs in Warnings & Precautions and Boxed Warnings sections.
• Statistical modeling to assess the impact of time, drug type (small molecules vs. monoclonal antibodies), and companion diagnostics on ADR emergence.

Main Results:

• Time was a significant predictor for new Warnings & Precautions (WPs) and Boxed Warnings (BWs).
• Small molecule TAAs showed a significantly higher number of new WPs compared to monoclonal antibodies.
• Companion diagnostics did not influence the emergence of new ADRs.

Conclusions:

• Serious ADRs for TAAs continue to emerge in updated labels years after initial approval.
• The risk-benefit profiles of approved TAAs are dynamic and require ongoing monitoring.
• Oncologists, regulators, and payers must remain aware of these evolving safety data.